Log in
NYSE:MYOV

Myovant Sciences Competitors

$21.85
+0.39 (+1.82 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$20.97
Now: $21.85
$22.16
50-Day Range
$13.80
MA: $16.46
$21.46
52-Week Range
$5.98
Now: $21.85
$23.04
Volume528,446 shs
Average Volume1.05 million shs
Market Capitalization$1.98 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.6

Competitors

Myovant Sciences (NYSE:MYOV) Vs. JAZZ, GLPG, RARE, IONS, BHC, and PRGO

Should you be buying MYOV stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Myovant Sciences, including Jazz Pharmaceuticals (JAZZ), Galapagos (GLPG), Ultragenyx Pharmaceutical (RARE), Ionis Pharmaceuticals (IONS), Bausch Health Companies (BHC), and Perrigo (PRGO).

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Myovant Sciences (NYSE:MYOV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Risk and Volatility

Jazz Pharmaceuticals has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Myovant Sciences has a beta of 2.6, meaning that its stock price is 160% more volatile than the S&P 500.

Valuation and Earnings

This table compares Jazz Pharmaceuticals and Myovant Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion3.66$523.37 million$14.609.71
Myovant SciencesN/AN/A$-288,990,000.00($3.37)-6.48

Jazz Pharmaceuticals has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

92.8% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.6% of Myovant Sciences shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 3.9% of Myovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Jazz Pharmaceuticals and Myovant Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals111502.82
Myovant Sciences01402.80

Jazz Pharmaceuticals presently has a consensus target price of $172.1176, indicating a potential upside of 21.35%. Myovant Sciences has a consensus target price of $32.25, indicating a potential upside of 47.60%. Given Myovant Sciences' higher probable upside, analysts plainly believe Myovant Sciences is more favorable than Jazz Pharmaceuticals.

Profitability

This table compares Jazz Pharmaceuticals and Myovant Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals7.86%20.16%10.85%
Myovant SciencesN/AN/A-186.00%

Summary

Jazz Pharmaceuticals beats Myovant Sciences on 11 of the 13 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and Myovant Sciences (NYSE:MYOV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Valuation and Earnings

This table compares Galapagos and Myovant Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$1.00 billion7.86$167.83 million$5.4622.12
Myovant SciencesN/AN/A$-288,990,000.00($3.37)-6.48

Galapagos has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Galapagos has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Myovant Sciences has a beta of 2.6, meaning that its stock price is 160% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Galapagos and Myovant Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galapagos210402.13
Myovant Sciences01402.80

Galapagos presently has a consensus target price of $180.1538, indicating a potential upside of 49.16%. Myovant Sciences has a consensus target price of $32.25, indicating a potential upside of 47.60%. Given Galapagos' higher probable upside, research analysts plainly believe Galapagos is more favorable than Myovant Sciences.

Profitability

This table compares Galapagos and Myovant Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galapagos8.13%8.24%3.82%
Myovant SciencesN/AN/A-186.00%

Insider and Institutional Ownership

11.6% of Galapagos shares are owned by institutional investors. Comparatively, 35.6% of Myovant Sciences shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 3.9% of Myovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Galapagos beats Myovant Sciences on 7 of the 12 factors compared between the two stocks.

Myovant Sciences (NYSE:MYOV) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Earnings and Valuation

This table compares Myovant Sciences and Ultragenyx Pharmaceutical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myovant SciencesN/AN/A$-288,990,000.00($3.37)-6.48
Ultragenyx Pharmaceutical$103.71 million70.53$-402,730,000.00($7.36)-16.28

Myovant Sciences has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Myovant Sciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Myovant Sciences has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Myovant Sciences and Ultragenyx Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Myovant Sciences01402.80
Ultragenyx Pharmaceutical051202.71

Myovant Sciences presently has a consensus price target of $32.25, indicating a potential upside of 47.60%. Ultragenyx Pharmaceutical has a consensus price target of $94.7059, indicating a potential downside of 20.97%. Given Myovant Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Myovant Sciences is more favorable than Ultragenyx Pharmaceutical.

Profitability

This table compares Myovant Sciences and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Myovant SciencesN/AN/A-186.00%
Ultragenyx Pharmaceutical-188.51%-56.12%-33.03%

Insider and Institutional Ownership

35.6% of Myovant Sciences shares are owned by institutional investors. 3.9% of Myovant Sciences shares are owned by insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Myovant Sciences beats Ultragenyx Pharmaceutical on 9 of the 13 factors compared between the two stocks.

Myovant Sciences (NYSE:MYOV) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Earnings and Valuation

This table compares Myovant Sciences and Ionis Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myovant SciencesN/AN/A$-288,990,000.00($3.37)-6.48
Ionis Pharmaceuticals$1.12 billion6.26$303.26 million$2.0824.15

Ionis Pharmaceuticals has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Myovant Sciences has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Myovant Sciences and Ionis Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Myovant Sciences01402.80
Ionis Pharmaceuticals16602.38

Myovant Sciences presently has a consensus price target of $32.25, indicating a potential upside of 47.60%. Ionis Pharmaceuticals has a consensus price target of $68.1818, indicating a potential upside of 35.71%. Given Myovant Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Myovant Sciences is more favorable than Ionis Pharmaceuticals.

Profitability

This table compares Myovant Sciences and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Myovant SciencesN/AN/A-186.00%
Ionis Pharmaceuticals7.82%6.56%3.38%

Insider and Institutional Ownership

35.6% of Myovant Sciences shares are owned by institutional investors. Comparatively, 85.4% of Ionis Pharmaceuticals shares are owned by institutional investors. 3.9% of Myovant Sciences shares are owned by insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Ionis Pharmaceuticals beats Myovant Sciences on 9 of the 13 factors compared between the two stocks.

Myovant Sciences (NYSE:MYOV) and Bausch Health Companies (NYSE:BHC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Earnings and Valuation

This table compares Myovant Sciences and Bausch Health Companies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myovant SciencesN/AN/A$-288,990,000.00($3.37)-6.48
Bausch Health Companies$8.60 billion0.79$-1,788,000,000.00$4.434.33

Myovant Sciences has higher earnings, but lower revenue than Bausch Health Companies. Myovant Sciences is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Myovant Sciences has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Myovant Sciences and Bausch Health Companies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Myovant Sciences01402.80
Bausch Health Companies061002.63

Myovant Sciences presently has a consensus price target of $32.25, indicating a potential upside of 47.60%. Bausch Health Companies has a consensus price target of $29.75, indicating a potential upside of 55.19%. Given Bausch Health Companies' higher probable upside, analysts plainly believe Bausch Health Companies is more favorable than Myovant Sciences.

Profitability

This table compares Myovant Sciences and Bausch Health Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Myovant SciencesN/AN/A-186.00%
Bausch Health Companies-23.92%173.20%4.21%

Insider and Institutional Ownership

35.6% of Myovant Sciences shares are owned by institutional investors. Comparatively, 62.2% of Bausch Health Companies shares are owned by institutional investors. 3.9% of Myovant Sciences shares are owned by insiders. Comparatively, 12.1% of Bausch Health Companies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Bausch Health Companies beats Myovant Sciences on 9 of the 13 factors compared between the two stocks.

Myovant Sciences (NYSE:MYOV) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Earnings and Valuation

This table compares Myovant Sciences and Perrigo's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myovant SciencesN/AN/A$-288,990,000.00($3.37)-6.48
Perrigo$4.84 billion1.35$146.10 million$4.0311.89

Perrigo has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Myovant Sciences has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Myovant Sciences and Perrigo, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Myovant Sciences01402.80
Perrigo03402.57

Myovant Sciences presently has a consensus price target of $32.25, indicating a potential upside of 47.60%. Perrigo has a consensus price target of $58.3333, indicating a potential upside of 21.71%. Given Myovant Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Myovant Sciences is more favorable than Perrigo.

Profitability

This table compares Myovant Sciences and Perrigo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Myovant SciencesN/AN/A-186.00%
Perrigo4.73%10.05%5.06%

Insider and Institutional Ownership

35.6% of Myovant Sciences shares are owned by institutional investors. Comparatively, 83.5% of Perrigo shares are owned by institutional investors. 3.9% of Myovant Sciences shares are owned by insiders. Comparatively, 0.3% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Perrigo beats Myovant Sciences on 8 of the 12 factors compared between the two stocks.


Myovant Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$141.83+0.7%$7.90 billion$2.16 billion44.74
Galapagos logo
GLPG
Galapagos
1.3$120.78+2.3%$7.89 billion$1.00 billion-18.30Analyst Report
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.3$119.83+0.8%$7.32 billion$103.71 million-22.96Analyst Report
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.8$50.24+0.4%$7.02 billion$1.12 billion104.67Insider Selling
Unusual Options Activity
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$19.17+0.4%$6.81 billion$8.60 billion-3.52
Perrigo logo
PRGO
Perrigo
2.4$47.93+1.0%$6.54 billion$4.84 billion27.55
Zai Lab logo
ZLAB
Zai Lab
1.2$106.69+0.3%$6.20 billion$12.98 million-35.21
United Therapeutics logo
UTHR
United Therapeutics
1.4$135.07+0.3%$6.00 billion$1.45 billion13.87
BBIO
BridgeBio Pharma
1.4$48.47+3.1%$5.94 billion$40.56 million-14.21
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$22.76+1.0%$5.93 billion$182.24 million-19.79
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.9$105.32+1.9%$5.87 billion$66.51 million19.43
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.6$57.02+5.9%$5.83 billion$168.80 million-228.08Earnings Announcement
Analyst Report
Analyst Revision
Allakos logo
ALLK
Allakos
1.0$103.73+1.4%$5.45 billionN/A-37.86
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.2$89.62+0.6%$5.37 billionN/A-7.30Insider Buying
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.6$151.89+8.3%$5.15 billion$26.52 million-14.16Analyst Upgrade
TPTX
Turning Point Therapeutics
1.7$106.05+1.4%$5.11 billionN/A-28.51
SDGR
Schrödinger
1.7$63.60+4.1%$4.42 billion$85.54 million0.00Analyst Upgrade
Insider Selling
Unusual Options Activity
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.1$63.53+0.6%$4.34 billion$306.98 million-9.05
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.2$82.70+3.4%$4.30 billion$6.87 million-7.01
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$80.41+1.5%$4.26 billion$1.11 billion25.86
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$31.06+0.1%$4.14 billion$204.89 million-38.83
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.7$127.61+1.3%$3.96 billion$311.33 million-74.19Insider Selling
Insmed logo
INSM
Insmed
1.1$38.58+3.0%$3.93 billion$136.47 million-14.84Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$29.49+0.4%$3.88 billion$150,000.00-14.18
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.50+0.2%$3.81 billion$806.43 million-9.28
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$54.00+3.6%$3.74 billion$36.13 million-80.60
FibroGen logo
FGEN
FibroGen
1.6$40.02+3.3%$3.64 billion$256.58 million-15.33Analyst Downgrade
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.5$47.46+0.3%$3.59 billionN/A-6.40Analyst Report
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.4$61.80+0.1%$3.52 billion$25 million-12.36Analyst Revision
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.2$88.71+3.0%$3.43 billion$26.69 million-33.48
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.8$45.66+0.7%$3.16 billion$117.91 million-9.26Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.7$16.48+1.3%$2.96 billion$114.62 million-6.65Insider Selling
Alkermes logo
ALKS
Alkermes
1.3$18.43+0.3%$2.93 billion$1.17 billion-40.06
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.2$63.36+1.5%$2.75 billion$421.03 million-253.44
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$73.42+1.5%$2.74 billionN/A-27.29
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.6$43.85+0.6%$2.71 billion$2.11 million-9.49
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$29.39+4.4%$2.68 billion$34.51 million-28.26Analyst Report
Unusual Options Activity
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$22.83+0.2%$2.65 billion$306.49 million25.65Analyst Revision
OPKO Health logo
OPK
OPKO Health
1.9$3.95+1.0%$2.65 billion$901.90 million-11.97
KRTX
Karuna Therapeutics
1.6$97.99+0.9%$2.63 billionN/A-48.75
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.3$68.57+1.8%$2.62 billion$644.77 million-10.19Analyst Report
Xencor logo
XNCR
Xencor
1.0$40.97+0.0%$2.35 billion$156.70 million-29.26
Zymeworks logo
ZYME
Zymeworks
1.2$48.55+1.6%$2.22 billion$29.54 million-12.88
IMAB
I-Mab
0.9$37.00+0.4%$2.11 billion$4.31 million-1.28
uniQure logo
QURE
uniQure
1.8$46.50+0.1%$2.07 billion$7.28 million-14.81Analyst Report
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$25.59+0.3%$2.05 billion$60,000.00-8.36
Kura Oncology logo
KURA
Kura Oncology
1.4$35.57+2.2%$2.02 billionN/A-21.82
IGMS
IGM Biosciences
2.1$64.50+2.8%$1.98 billionN/A-27.45
ZNTL
Zentalis Pharmaceuticals
1.4$46.04+0.8%$1.87 billionN/A0.00Insider Buying
Heavy News Reporting
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.3$11.63+1.1%$1.86 billion$428.41 million16.86
This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.